Halozyme Therapeutics — May 11, 2026 release

The five signed Hypercon agreements, which include the opportunity for 17 targets to be developed, with first approvals projected in the 2030/2031 time period represents a third exciting wave of new royalty revenue opportunity. This continued performance and progress resulted in strong first quarter financial results and we are pleased to reaffirm our 2026 outlook, including expectations for ENHANZE royalty revenue to exceed $1 billion for the full year,” Dr. Torley concluded. Recent Corporate Highlights: • In May 2026, the Company announced a new share repurchase program to repurchase up to $1 billion of its outstanding common stock by December 31, 2028, with an expectation of buying back at least $400 million of shares in 2026. Recent Partner Highlights: • In May 2026, argenx announced U.S. Food and Drug Administration (“FDA”) approval of a supplemental Biologics License Application (“sBLA”) for VYVGART ® Hytrulo with ENHANZE ® for the treatment of adult patients with generalized myasthenia gravis (“gMG”) including all serotypes – anti-AChR-Ab positive, anti-MuSK-Ab positive, anti-LRP4-Ab positive, and triple seronegative. • In May 2026, Halozyme and GSK plc (“GSK”) entered into a global collaboration and license agreement for ENHANZE ® with multiple oncology targets, including the first potential application in antibody-drug conjugates (“ADCs”). Under the terms of the agreement, GSK will make an upfront payment and potential future milestone payments and royalties on net sales of products developed with ENHANZE ® . • In May 2026, Halozyme and Oruka Therapeutics, Inc. (“Oruka”) entered into a global exclusive